TruNativ bags $30M Series B led by OrbiMed to scale clean-label nutrition play

Mumbai-based D2C nutrition brand TruNativ has raised $30M in Series B (primary + secondary) led by OrbiMed. Capital will fund expansion across D2C, quick commerce, modern trade, and pharmacy, plus growth of its B2B2C ingredient business spanning sugar substitutes, protein, gut health, and wellness.

— Source publishedTue, 16 Jun, 2026, 19:52 IST·First seen Tue, 16 Jun, 2026, 19:54 IST·Source YourStory

What happened

Mumbai-based clean-label nutrition D2C brand TruNativ raised $30M Series B led by OrbiMed (primary plus secondary). Funds will scale distribution across D2C,

Key facts

  • $30M Series B
  • founded 2019
  • 5 nutrition categories
  • OrbiMed AUM ~$20B

Why this matters

TruNativ's dual D2C + B2B2C ingredient model (sugar substitutes, protein, gut health) makes it a strategic bolt-on target for FMCG majors or pharma players seeking instant clean-label portfolio depth and ingredient supply leverage.

Also reported by